Search the Newsreel

Q3 EPS Estimates for Journey Medical Cut by HC Wainwright

We Think Veradermics (NYSE:MANE) Can Afford To Drive Business Growth

Journey Medical (FBIO) Q2 2026 Earnings Call: Revenue Rises 23% as Emrosi Accelerates

Journey Medical (FBIO) reported a 23% year-over-year revenue increase to $18.5 million in Q2 2026, primarily driven by strong performance from its rosacea product, Emrosi, which generated $8.1 million in net revenue and saw a 20% sequential rise in prescriptions. The company achieved positive …

Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving?

Dermata Therapeutics Inc. (NASDAQ: DRMA) stock surged 27.78% pre-market after the company reported its second-quarter results. Despite missing analyst estimates for earnings per share, the company is preparing to launch its first commercial skincare product, Tome Foundational Treatment, on August 25. Dermata Therapeutics aims …

Journey Medical's (DERM) Buy Rating Reaffirmed at B. Riley Financial

B. Riley Financial has reaffirmed its "Buy" rating for Journey Medical (NASDAQ:DERM), increasing its price target from $12 to $15, which suggests a 133.28% potential upside. Despite mixed analyst opinions, the company recently surpassed quarterly expectations, reporting an adjusted loss of $0.01 per share …

Why is Journey Medical stock rallying today?

Journey Medical Corp (DERM) stock surged 10.9% in pre-open trading after reporting second-quarter 2026 results that significantly surpassed analyst expectations for both earnings and revenue. The company posted adjusted EPS of $0.10 against an estimated loss of $0.02, with revenue hitting $18.5 million, exceeding …

DRMA|Dermata Therapeutics Inc|Price:1.370|Chg%:+0.290

This article provides a detailed overview of Dermata Therapeutics Inc (DRMA) stock performance, financial data, and analyst ratings. It highlights the company's focus on medical dermatology and its two main product candidates, XYNGARI and DMT410, which utilize Spongilla technology for various skin conditions. The …

Needham Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $164

Needham has reiterated its Buy rating for Veradermics (MANE.US) and maintained its price target of $164. This indicates continued confidence in the company's stock performance by the investment firm.

Journey Medical Corporation Q2 2026 Earnings Call Summary

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings

Earnings call transcript: Journey Medical posts Q2 2026 revenue gain, turns EBITDA positive

Journey Medical Corp. reported a 23% year-over-year revenue increase in Q2 2026, reaching $18.5 million, primarily driven by strong sales of its rosacea drug, EMROSI. The company significantly narrowed its GAAP net loss to $300,000 and achieved positive EBITDA of $1.4 million. Management projects …

Veradermics, Inc SEC Filing (Aug 12, 2026)

This article details an SEC Form 144 filing by Veradermics, Inc. (MANE) on August 12, 2026. The filing indicates a proposed sale of 104,587 shares of common stock with an aggregate market value of $11,394,753.65 through Merrill Lynch. The shares were acquired via a …

Earnings call transcript: Journey Medical tops Q2 2026 forecasts as stock rises

Journey Medical earnings beat by $0.12, revenue topped estimates

Journey Medical (DERM) grows Emrosi sales but flags going concern risk

Journey Medical (NASDAQ:DERM) Posts Earnings Results, Beats Expectations By $0.04 EPS

Journey Medical (NASDAQ:DERM) reported its earnings results, beating consensus EPS expectations by $0.04 with a loss of $0.01 per share and exceeding revenue estimates with $18.51 million. Despite beating expectations, the company remains unprofitable with a negative net margin and return on equity, and …

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Journey Medical Corporation (DERM) reported a Q2 loss of $0.01 per share, which was in line with Zacks Consensus Estimate, but missed revenue estimates with $18.51 million against an expectation of $1.1% higher. The company's shares have declined by 18% year-to-date, contrasting with the …

DRMA Stock In Focus As Dermata Pivots To Direct-To-Consumer Skincare

Dermata Therapeutics (DRMA) stock is gaining attention due to its strategic pivot from prescription dermatology to direct-to-consumer skincare with the upcoming launch of Tome Foundational Treatment on August 25, 2026. This move aims to establish a recurring revenue stream, shifting the company's business model. …

DRMA Stock Draws Traders As Dermata Pivots To Skincare Launch

Dermata Therapeutics (DRMA) stock is seeing increased trading activity and positive sentiment due to its strategic pivot towards a direct-to-consumer skincare market. The company is set to launch "Tome Foundational Treatment," its first skincare product utilizing Bioneedle technology, on August 25, 2026. This move …

Veradermics: Q2 Earnings Snapshot

Veradermics Inc. (MANE) reported a significant loss of $23.5 million, or 58 cents per share, in its second quarter. The New Haven, Connecticut-based company's financial results were disclosed on Tuesday, August 11, 2026. This data was compiled by Automated Insights using information from Zacks …

Dermata Therapeutics Shares Jump 28.73% Pre-Market - Dermata Therapeutics (NASDAQ:DRMA)

Dermata Therapeutics Reports Q2 2026 Results Ahead Of First Product Launch; Stock Up

(RTTNews) - Dermata Therapeutics, Inc. (DRMA) announced financial results for the second quarter ended June 30, 2026, alongside a corporate update highlighting its transition into a commercial-stage skincare company. The San Diego-based firm is preparing to launch its first direct-to-consumer product, Tome Foundational Treatment, …

DERMATA THERAPEUTICS ($DRMA) Releases Q2 2026 Earnings, Stock Rises

DERMATA THERAPEUTICS ($DRMA) released its Q2 2026 earnings, reporting -$0.74 per share, missing estimates by $0.18, with revenue matching expectations at $0. Despite missing earnings estimates, the stock price rose by 43.66% since market close. The article also details recent insider trading activity, including …

Veradermics Q2 Results: EPS of $(0.58) Beats Estimate

Trending Stocks Today | Dermata Therapeutics Soars 35.18% Post-Market

Dermata Therapeutics (DRMA) experienced a significant post-market surge of 35.18%. This jump follows the company's announcement of positive topline data from its Phase 2b trial for DMT310 in treating moderate-to-severe rosacea. The results showed statistically significant improvements in inflammatory lesion count, erythema, and Global …

12 Health Care Stocks Moving In Tuesday's After-Market Session

This article details the performance of 12 health care stocks during Tuesday's after-market session, highlighting both gainers and losers. Several companies, including Dermata Therapeutics and CytoSorbents, saw their stock prices increase, often coinciding with recent Q2 earnings reports. Conversely, stocks like Edap TMS and …

Veradermics (NYSE: MANE) posts larger loss as cash surges above $800M

Veradermics (NYSE: MANE) reported a significantly larger net loss of $50.7 million for the first half of 2026, compared to $28.0 million in the prior year, primarily due to increased operating expenses in research and development and general and administrative costs. Despite the losses, …

DRMA Financials: Income Statement, Balance Sheet & Cash Flow

Dermata Therapeutics (DRMA) faces going concern warning amid higher losses and cash burn

Dermata's Tome Skincare Product Is Designed for Once-Weekly Use

Dermata Therapeutics (NASDAQ:DRMA) announced its Q2 2026 financial results, revealing a strategic pivot to a direct-to-consumer skincare model. The company is set to launch its first product, Tome Foundational Treatment, on August 25, 2026, with manufacturing and packaging complete. Despite a net loss of …

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Dermata Therapeutics (NASDAQ: DRMA) announced its financial results for the second quarter of 2026 and provided a corporate update, highlighting its transition to a commercial-stage, direct-to-consumer skincare company. The company expects to launch its first commercial product, Tome™ Foundational Treatment, on August 25, 2026, …

Veradermics reports Q2 2026 net loss $23.5M; cash $819.9M funds operations into 2030

Veradermics reported a net loss of $23.5 million for Q2 2026, an increase from $15.6 million in Q2 2025, driven by higher R&D and G&A expenses. Despite the loss, the company holds a strong cash position of $819.9 million, expected to fund operations into …

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics announced positive second-quarter 2026 financial results and significant clinical progress for its lead drug candidate, VDPHL01, an extended-release oral minoxidil for pattern hair loss. The company reported positive Phase 2 results for female pattern hair loss, completed enrollment for a pivotal Phase 2/3 …